deltatrials
Unknown PHASE1 INTERVENTIONAL 1-arm NCT02500199

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy

Sponsor: Hengrui Therapeutics, Inc.

Conditions Breast Cancer Gastric Cancer NSCLC Solid Tumors
Interventions Pyrotinib
Updated 15 times since 2017 Last updated: Jan 28, 2021 Started: Jun 30, 2015 Primary completion: May 31, 2021 Completion: Jun 30, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02500199, this PHASE1 trial focuses on Breast Cancer and Gastric Cancer and remains ongoing. Sponsored by Hengrui Therapeutics, Inc., it has been updated 15 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Dec 2017 · 4 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~Mar 2020 · 11 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Feb 2023 · 23 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1

    Status: Unknown Status → Unknown

  4. Feb 2023 — Jul 2024 [monthly]

    Unknown Status PHASE1

    Status: Active Not Recruiting → Unknown Status

  5. Mar 2021 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1

▶ Show 10 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Apr 2019 — Mar 2020 [monthly]

    Recruiting PHASE1

  4. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE1

  5. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  6. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE1

  7. Aug 2017 — Dec 2017 [monthly]

    Recruiting PHASE1

  8. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE1

  9. Feb 2017 — Jul 2017 [monthly]

    Recruiting PHASE1

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hengrui Therapeutics, Inc.
Data source: Hengrui Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations